Literature DB >> 29138101

Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study.

D-S Liu1, Y-H Wang1, Z-R Zeng2, Z-Y Zhang3, H Lu4, J-M Xu5, Y-Q Du6, Y Li7, J-B Wang8, S-P Xu9, Y Chen10, C-H Lan11, H Cheng12, M-D Jiang13, L-X Zhang14, L-J Huo15, S-Y Chen16, G-X Zhang17, K-C Wu18, X Zhu1, Y-X Chen1, Y Zhu1, X Shu1, Y Xie19, N-H Lu20.   

Abstract

OBJECTIVES: To explore the characteristics of Helicobacter pylori resistance in China and the association between antibiotic resistance and several clinical factors.
METHODS: H. pylori strains were collected from patients in 13 provinces or cities in China between 2010 and 2016. Demographic data including type of disease, geographic area, age, gender and isolation year were collected to analyse their association with antibiotic resistance. Antibiotic resistance was detected using the Etest test and the Kirby-Bauer disc diffusion method.
RESULTS: H. pylori were successfully cultured from 1117 patients. The prevalence of metronidazole, clarithromycin (CLA), azithromycin, levofloxacin (LEV), moxifloxacin, amoxicillin (AMO), tetracycline and rifampicin resistance was 78.2, 22.1, 23.3, 19.2, 17.2, 3.4, 1.9 and 1.5%, respectively. No resistance to furazolidone was observed. The resistance rates to LEV and moxifloxacin were higher in strains isolated from patients with gastritis compared to those with duodenal ulcer and among women. Compared to patients ≥40 years old, younger patients exhibited lower resistance rates to CLA, azithromycin, LEV and moxifloxacin. The resistance rates to CLA and AMO were higher in strains isolated more recently, and we also found that the prevalence of resistance to metronidazole, CLA, azithromycin and AMO were significantly different among different regions of China.
CONCLUSIONS: The resistance rates to metronidazole, CLA and LEV were high in China. Patient age, gender, disease and location were associated with the resistance of H. pylori to some antibiotics. Furazolidone, AMO and tetracycline are better choices for H. pylori treatment in China.
Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; China; Clinical factors; Helicobacter pylori; Multiregion

Mesh:

Substances:

Year:  2017        PMID: 29138101     DOI: 10.1016/j.cmi.2017.11.010

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  18 in total

1.  Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial.

Authors:  Luyi Chen; Jiamin He; Lan Wang; Qiwei Ge; Hua Chu; Yujia Chen; Xiaoli Chen; Yanqin Long; Yanyong Deng; Huiqin He; Aiqing Li; Shujie Chen
Journal:  Clin Exp Med       Date:  2018-06-06       Impact factor: 3.984

2.  A Survey of Helicobacter pylori Antibiotic-Resistant Genotypes and Strain Lineages by Whole-Genome Sequencing in China.

Authors:  Yan Zhou; Zishao Zhong; Shengjuan Hu; Jing Wang; Yanhong Deng; Ximei Li; Xianmei Chen; Xue Li; Yuanyuan Tang; Xiaofei Li; Qian Hao; Jun Liu; Tian Sang; Yang Bo; Feihu Bai
Journal:  Antimicrob Agents Chemother       Date:  2022-06-02       Impact factor: 5.938

3.  Efficacy of tailored second-line therapy of Helicobacter pylori eradication in patients with clarithromycin-based treatment failure: a multicenter prospective study.

Authors:  Siya Kong; Keting Huang; Jun Wang; Guoxin Zhang; Feng Ye; Xiaoyong Wang; Ningmin Yang; Yu Dong; Ya Zhuang; Yini Dang
Journal:  Gut Pathog       Date:  2020-08-29       Impact factor: 4.181

4.  Genotype profiles of Helicobacter pylori from gastric biopsies and strains with antimicrobial-induced resistance.

Authors:  You-Hua Wang; Fang-Fei Wang; Xiao-Ling Gong; Li-Li Yan; Qiao-Yun Zhao; Yan-Ping Song; Ru-Lin Zhao; Ya-Jing He; Linfu Zhou; Dong-Sheng Liu; Yong Xie
Journal:  Therap Adv Gastroenterol       Date:  2020-09-24       Impact factor: 4.409

5.  Antibiotic Resistance of Helicobacter pylori Isolated from Patients after Partial Gastrectomy: A Retrospective Study.

Authors:  Lan Li; Weihua Zhou; Hongzhang Li; Chaohui Yu; Tianlian Yan; Ningmin Yang; You-Ming Li
Journal:  Turk J Gastroenterol       Date:  2021-12       Impact factor: 1.555

6.  Fourth-generation quinolones in the treatment of Helicobacter pylori infection: A meta-analysis.

Authors:  Ying An; Ya Wang; Shuang Wu; You-Hua Wang; Xing Qian; Zhen Li; Ying-Jun Fu; Yong Xie
Journal:  World J Gastroenterol       Date:  2018-08-07       Impact factor: 5.742

7.  Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study.

Authors:  Dong-Min Yi; Tao-Tao Yang; Shuai-Heng Chao; Ya-Xin Li; Ying-Lei Zhou; Hai-Hui Zhang; Ling Lan; Yu-Wei Zhang; Xue-Mei Wang; Yan-Rui Zhang; Jian Li; Song-Ze Ding
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.889

Review 8.  Update on quinolone-containing rescue therapies for Helicobacter pylori infection.

Authors:  Hideki Mori; Hidekazu Suzuki
Journal:  World J Gastroenterol       Date:  2020-04-21       Impact factor: 5.742

9.  Early genetic diagnosis of clarithromycin resistance in Helicobacter pylori.

Authors:  Xiao-Hua Li; Yong-Yi Huang; Lin-Ming Lu; Li-Juan Zhao; Xian-Ke Luo; Ru-Jia Li; Yuan-Yuan Dai; Chun Qin; Yan-Qiang Huang; Hao Chen
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

10.  Identifying the best regimen for primary eradication of Helicobacter pylori: analysis of 240 cases.

Authors:  Yao Chen; Qingyi Liu; Fulian Hu; Jizheng Ma
Journal:  Microbiologyopen       Date:  2020-10-07       Impact factor: 3.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.